- Home
- SFWL vs AVTE Comparison
SFWL vs AVTE Comparison
Compare SFWL & AVTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- AVTE
- Stock Information
- Founded
- SFWL 2001
- AVTE 2018
- Country
- SFWL China
- AVTE United States
- Employees
- SFWL 1263
- AVTE N/A
- Industry
- SFWL Trucking Freight/Courier Services
- AVTE Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- AVTE Health Care
- Exchange
- SFWL Nasdaq
- AVTE Nasdaq
- Market Cap
- SFWL 74.2M
- AVTE 72.5M
- IPO Year
- SFWL 2023
- AVTE 2021
- Fundamental
- Price
- SFWL $0.90
- AVTE $2.75
- Analyst Decision
- SFWL
- AVTE Hold
- Analyst Count
- SFWL 0
- AVTE 7
- Target Price
- SFWL N/A
- AVTE $11.75
- AVG Volume (30 Days)
- SFWL 12.4K
- AVTE 192.3K
- Earning Date
- SFWL 04-29-2025
- AVTE 05-12-2025
- Dividend Yield
- SFWL N/A
- AVTE N/A
- EPS Growth
- SFWL 4.79
- AVTE N/A
- EPS
- SFWL 0.13
- AVTE N/A
- Revenue
- SFWL $504,158,000.00
- AVTE N/A
- Revenue This Year
- SFWL N/A
- AVTE N/A
- Revenue Next Year
- SFWL N/A
- AVTE N/A
- P/E Ratio
- SFWL $6.83
- AVTE N/A
- Revenue Growth
- SFWL 24.75
- AVTE N/A
- 52 Week Low
- SFWL $0.81
- AVTE $1.25
- 52 Week High
- SFWL $2.18
- AVTE $25.29
- Technical
- Relative Strength Index (RSI)
- SFWL 38.24
- AVTE 72.33
- Support Level
- SFWL $0.87
- AVTE $2.61
- Resistance Level
- SFWL $0.95
- AVTE $2.82
- Average True Range (ATR)
- SFWL 0.06
- AVTE 0.11
- MACD
- SFWL -0.01
- AVTE 0.02
- Stochastic Oscillator
- SFWL 20.63
- AVTE 81.08
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About AVTE Aerovate Therapeutics Inc.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.